• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • Skip to investors navigation
Scholar Rock

Scholar Rock

Discovery and Development of Innovative Medicines

  • Careers
  • Newsroom
  • Contact Us
  • Patients & Families
    • Patients & Families
    • Areas of Focus
      • Spinal Muscular Atrophy
    • Patient Stories
    • Clinical Trials
    • Resources
    • Expanded Access

    Learn about our commitment to creating possibilities for those living with serious disease.

    Patients & Families

  • Our Company
    • Our Company
    • Mission & Vision
    • Newsroom
    • Careers
    • Management Team
    • Board of Directors

    Meet Scholar Rock, a biopharmaceutical company committed to improving lives.

    Our Company

  • Our Science
    • Our Science
    • Platform
    • Publications & Posters

    Discover how our breakthrough approach treats complex disease at its biological root.

    Our Science

  • Our Pipeline
    • Our Pipeline
    • Neuromuscular and Obesity
      • Spinal Muscular Atrophy
      • Cardiometabolic Disorders
    • Immuno-Oncology
      • Cancer (solid tumors)
    • Fibrotic Diseases
      • Fibrosis
    • Hematology
      • Anemia
  • Investors & Media
    • Investor Overview
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
HomePatients & FamiliesClinical Trials

Clinical Trials

The process from lab to patient

We believe in our investigational medicines and their potential to change patients’ lives. Clinical trials are a critical step in bringing a new therapy from our in-house laboratory to the world.

Read below for important background information and the most recent updates on our clinical trials.

Jump to:

Neuromuscular and Cardiometabolic Disorders

Immunology and Oncology

Neuromuscular and Cardiometabolic Disorders

TOPAZ

Spinal Muscular Atrophy

TOPAZ

The TOPAZ trial was a proof-of-concept, open-label Phase 2 trial evaluating the safety and efficacy of apitegromab in patients with Type 2 and Type 3 SMA. In the main treatment period, participants were dosed intravenously every four weeks as monotherapy or with nusinersen, an approved SMN-targeted therapy. The trial enrolled 58 participants in the U.S. and Europe. The primary efficacy endpoints were mean change from baseline in Revised Hammersmith Scale (RHS) score at 12 months for the ambulatory population (Cohort 1), and mean change from baseline in HFMSE score at 12 months for the non-ambulatory population (Cohorts 2 and 3). The trial also included multiple 12-month extension periods designed to evaluate longer-term participant outcomes.

View 12-month results here and 36-month results here.

Learn More About TOPAZ at clinicaltrials.gov

SAPPHIRE

Spinal Muscular Atrophy

SAPPHIRE

SAPPHIRE was a randomized, double-blind, placebo-controlled Phase 3 clinical trial that evaluated the safety and efficacy of apitegromab in non-ambulatory patients with Types 2 and 3 SMA who are receiving current standard of care (either nusinersen or risdiplam). SAPPHIRE enrolled 156 patients aged 2-12 years old in the main efficacy population. These patients were randomized 1:1:1 to receive for 12 months either apitegromab 10 mg/kg, apitegromab 20 mg/kg, or placebo by intravenous (IV) infusion every 4 weeks. An exploratory population that enrolled 32 patients aged 13-21 years old was also evaluated. These patients were randomized 2:1 to receive either apitegromab 20 mg/kg or placebo.

Learn more about SAPPHIRE at clinicaltrials.gov

ONYX

Spinal Muscular Atrophy

ONYX

ONYX is an open-label Phase 3 study designed to assess the long-term safety and efficacy of apitegromab in participants with Type 2 and Type 3 SMA who have completed the TOPAZ or SAPPHIRE trial.

Learn more about ONYX at clinicaltrials.gov

EMBRAZE

Cardiometabolic Disorders

EMBRAZE

EMBRAZE is a randomized, double-blind, placebo-controlled, Phase 2 proof-of-concept trial evaluating apitegromab in adults with a body mass index (BMI) of >27 (overweight) or a BMI of >30 (obese) and taking a GLP-1 RA (tirzepatide or semaglutide). The target enrollment of EMBRAZE is 100 participants aged 18-65 who are overweight or obese without diabetes. As part of the 24-week-long study design, all participants will receive a GLP-1 RA. In addition, all participants will be randomized 1:1 to receive either apitegromab or placebo by intravenous (IV) infusion every four weeks during the 24-week treatment period. Results from the EMBRAZE trial will inform the development of SRK-439, a novel, preclinical muscle-targeted therapy designed to support healthier weight management and lean muscle preservation during and after treatment with obesity therapies.

Primary data from EMBRAZE are expected in mid-2025.

Learn more about EMBRAZE at clinicaltrials.gov

Immunology and Oncology

DRAGON

Cancer (locally advanced or metastatic solid tumors)

DRAGON

The DRAGON trial is investigating SRK-181, a selective inhibitor of TGFβ1 activation, in participants with locally advanced or metastatic solid tumors that have shown primary resistance to checkpoint inhibitor therapies. Part A was designed to assess safety and tolerability of SRK-181. With some results of Part A available, the Part B dose expansion portion evaluated SRK-181 in combination with an approved anti-PD-(L)1 therapy across multiple solid tumor trial groups to test proof of concept. The results from the combination therapy trial showed encouraging responses in heavily pretreated and anti-PD-(L)1 resistant participants across multiple tumor types. Additional results from the Part B dose expansion can be found here.

Learn more about DRAGON at clinicaltrials.gov

Expanded Access Policy

View Our Expanded Access Policy

Patients seeking more information on potential clinical trials should contact their physician.

Footer

Scholar Rock, Inc.
301 Binney Street, 3rd Floor
Cambridge, MA 02142

Phone: 857.259.3860
[email protected]

LinkedIn X, formally Twitter
© 2025 All Rights Reserved
  • Community Guidelines
  • Expanded Access
  • Privacy Policy
  • Terms of Use

We are Scholar Rock.

A biopharmaceutical company dedicated to discovering, developing, and delivering therapies that create new possibilities for patients.

Learn More About Our Pipeline

  • Community Guidelines
  • Expanded Access
  • Privacy Policy
  • Terms of Use
logo
  • Patients & Families
    • Areas of Focus
      • Spinal Muscular Atrophy
    • Patient Stories
    • Clinical Trials
    • Resources
    • Expanded Access
  • Our Company
    • Mission & Vision
    • Newsroom
    • Careers
    • Management Team
    • Board of Directors
    • Partnering
  • Our Science
    • Platform
    • Publications & Posters
  • Our Pipeline
    • Neuromuscular and Obesity
      • Spinal Muscular Atrophy
      • Cardiometabolic Disorders
    • Immuno-Oncology
      • Cancer (solid tumors)
    • Fibrotic Diseases
      • Fibrosis
    • Hematology
      • Anemia
  • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
  • Careers
  • Newsroom
  • Contact Us

You are now leaving the Scholar Rock website.

This external link is provided for your convenience. Scholar Rock is not responsible for content on external websites.

Continue